NuVasive yesterday reported Q1 results that beat on the top-line while falling slightly short of the Street's bottom line estimate, Piper Jaffray analyst Matt O'Brien tells investors in a research note. Gross margins were negatively impacted by manufacturing bottlenecks in the new Ohio manufacturing facility, but this is a short-term problem that should resolve during the second half of 2018, the analyst contends. He views the quarter as better than feared and believes that stabilization in the outlook makes NuVasive a name investors can own at these levels. O'Brien lowered his price for the shares to $65 from $90 and keeps an Overweight rating on the name.